Ivermectin Orion

Ivermectin, the active ingredient in Ivermectin Orion, is an antiparasitic (macrocyclic lactone) presented as an oral formulation for systemic use. It is employed to treat infections caused by nematodes and ectoparasites, including onchocerciasis, strongyloidiasis, scabies, and lymphatic filariasis, in adult and pediatric patients as directed by a healthcare professional.

GNH USA supplies Ivermectin Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Ivermectin acts on a range of helminthic and ectoparasitic infections, providing parasiticidal activity across several disease families.

- Onchocerciasis: reduces microfilarial load and helps prevent disease progression. - Strongyloidiasis: eradicates intestinal larvae and prevents disseminated infection. - Scabies: eliminates Sarcoptes mites, relieving skin lesions and itching. - Lymphatic filariasis: decreases circulating microfilariae, aiding in disease control programs.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient light‑headedness. - Pruritus: itching at the site of parasite death. - Headache: mild tension‑type pain. - Abdominal pain: cramping or discomfort. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: elevated liver enzymes or hepatitis. - Neurologic events: seizures, ataxia, or altered consciousness. - Hypotension: sudden drop in blood pressure. - Anaphylaxis: acute allergic reaction with airway compromise. - Vision changes: blurred vision or optic neuritis.

Before prescribing Ivermectin Orion, clinicians should consider several safety aspects.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion; weigh infant exposure against maternal benefit. - Liver disease: impaired metabolism may require dose adjustment. - Concomitant CNS depressants: monitor for enhanced sedation or respiratory depression. - Drug interactions: avoid strong CYP3A4 or P‑glycoprotein inhibitors without supervision. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivermectin may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase ivermectin plasma concentrations. - P‑glycoprotein inhibitors (e.g., verapamil): can raise systemic exposure. - Warfarin: may potentiate anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., carbamazepine): may reduce ivermectin effectiveness. - Other antiparasitics: additive toxicity potential. - Alcohol: may enhance central nervous system depression.